Paper2870533
A controlled trial of prostaglandin E1 precursor in chronic neuroleptic resistant schizophrenic patients.
Vaddadi KS and 3 others. Psychopharmacology (Berl), 1986. Cited by 45 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. A controlled trial of prostaglandin E1 precursor in chronic neuroleptic resistant schizophrenic patients. Papers, record 2870533. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2870533
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| 8,11,14-Eicosatrienoic Acid | Major topic |
| Alprostadil | Major topic |
| Antipsychotic Agents | Major topic |
| Fatty Acids, Unsaturated | Major topic |
| Schizophrenia | Major topic |
| Adult | |
| Clinical Trials as Topic | |
| Double-Blind Method | |
| Drug Resistance | |
| Erythrocyte Membrane | |
| Fatty Acids | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Psychiatric Status Rating Scales | |
| Psychomotor Performance | |
| Random Allocation | |
| Schizophrenic Psychology |
Source PubMed
References14
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 7,272,515 | Research findings on the nature of constructs in schizophrenics. | Br J Clin Psychol | 1981 | https://conductscience.org/library/papers/7272515 | PubMed |
| 2 | 347,911 | Dietary essential fatty acids, polyunsaturated fatty acids, and prostaglandins in the central nervous system. | Adv Prostaglandin Thromboxane Res | 1978 | https://conductscience.org/library/papers/347911 | PubMed |
| 3 | 67,391 | Schizophrenia as a prostaglandin deficiency disease. | Lancet | 1977 | https://conductscience.org/library/papers/67391 | PubMed |
| 4 | 920,483 | Dietary essential fatty acids, brain polyunsaturated fatty acids, and prostaglandin biosynthesis. | Adv Exp Med Biol | 1977 | https://conductscience.org/library/papers/920483 | PubMed |
| 5 | 11,519 | Possible association of schizophrenia with a disturbance in prostaglandin metabolism: a physiological hypothesis. | Psychol Med | 1976 | https://conductscience.org/library/papers/11519 | PubMed |
| 6 | 6,539,131 | Prostaglandin E1 treatment of schizophrenia. | Biol Psychiatry | 1984 | https://conductscience.org/library/papers/6539131 | PubMed |
| 7 | 338,112 | Antithrombotic potential of dihomo-gamma-linolenic acid in man. | Br Med J | 1977 | https://conductscience.org/library/papers/338112 | PubMed |
| 8 | 6,269,135 | The use of gamma-linolenic acid and linoleic acid to differentiate between temporal lobe epilepsy and schizophrenia. | Prostaglandins Med | 1981 | https://conductscience.org/library/papers/6269135 | PubMed |
| 9 | 5,009,428 | Diagnostic criteria for use in psychiatric research. | Arch Gen Psychiatry | 1972 | https://conductscience.org/library/papers/5009428 | PubMed |
| 10 | 436,735 | Prolactin and zinc effects on rat vascular reactivity: possible relationship to dihomo-gamma-linolenic acid and to prostaglandin synthesis. | Endocrinology | 1979 | https://conductscience.org/library/papers/436735 | PubMed |
| 11 | 7,342,120 | Changes in essential fatty acid profile of serum phospholipids in human disease. | Prog Lipid Res | 1981 | https://conductscience.org/library/papers/7342120 | PubMed |
| 12 | 996,201 | Clinical significance of plasma chlorpromazine levels. I. Plasma levels of the drug, some of its metabolites and prolactin during acute treatment. | Psychol Med | 1976 | https://conductscience.org/library/papers/996201 | PubMed |
| 13 | 7,402,143 | The regulation of prostaglandin biosynthesis: negative feedback mechanisms and the selective control of formation of I and 2 series prostaglandins: relevance to inflammation and immunity. | Med Hypotheses | 1980 | https://conductscience.org/library/papers/7402143 | PubMed |
| 14 | 121,601 | Penicillin and essential fatty acid supplementation in schizophrenia. | Prostaglandins Med | 1979 | https://conductscience.org/library/papers/121601 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 45 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,005,438 | Omega-3 fatty acids in mental disorders: from neurobiological and metabolic mechanisms to therapeutic potential. | Front Nutr | 2026 | https://conductscience.org/library/papers/42005438 | PubMed |
| 40,376,988 | Zinc in psychosis (Review). | Mol Med Rep | 2025 | https://conductscience.org/library/papers/40376988 | PubMed |
| 32,840,872 | Maintenance treatment with antipsychotic drugs for schizophrenia. | Cochrane Database Syst Rev | 2020 | https://conductscience.org/library/papers/32840872 | PubMed |
| 24,915,451 | Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders. | Cochrane Database Syst Rev | 2014 | https://conductscience.org/library/papers/24915451 | PubMed |
| 20,417,059 | Niacin sensitivity and the arachidonic acid pathway in schizophrenia. | Schizophr Res | 2010 | https://conductscience.org/library/papers/20417059 | PubMed |
| 16,855,961 | Polyunsaturated fatty acid supplementation for schizophrenia. | Cochrane Database Syst Rev | 2006 | https://conductscience.org/library/papers/16855961 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2870533
GET https://conductscience.org/api/papers/v1/2870533/authors